These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2335396)

  • 1. The CMF-regimen. Modulation of cyclophosphamide uptake and clearance by methotrexate and fluorouracil.
    De Bruijn EA; Geng Y; Hermans J; Driessen O
    Int J Cancer; 1990 May; 45(5):935-9. PubMed ID: 2335396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorouracil catabolism in the combination treatment of cyclophosphamide, methotrexate and fluorouracil.
    De Bruijn EA; Van der Heyden SA; Gheuens EE; Maes RA
    Jpn J Cancer Res; 1992 Oct; 83(10):1102-7. PubMed ID: 1452462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CMF-regimen. Toxicity patterns following stepwise combinations of cyclophosphamide, methotrexate and fluorouracil.
    De Bruijn EA; Driessen OM; Hermans J
    Int J Cancer; 1991 Apr; 48(1):67-72. PubMed ID: 2019458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of cyclophosphamide in the CMF regimen.
    Gheuens E; Slee PH; de Bruijn EA
    Onkologie; 1990 Jun; 13(3):203-6. PubMed ID: 2204007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of some anticancer drugs and combined chemotherapy on renal toxicity.
    Skretkowicz J; Sekulska M; Danilewicz M; Wagrowska-Danilewicz M; Polakowski P
    Biol Signals; 1996; 5(1):51-8. PubMed ID: 8739323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Batey MA; Wright JG; Azzabi A; Newell DR; Lind MJ; Calvert AH; Boddy AV
    Eur J Cancer; 2002 May; 38(8):1081-9. PubMed ID: 12008196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual role of vitamin C on lipid profile and combined application of cyclophosphamide, methotrexate and 5-fluorouracil treatment in fibrosarcoma-bearing rats.
    Muralikrishnan G; Amalan Stanley V; Sadasivan Pillai K
    Cancer Lett; 2001 Aug; 169(2):115-20. PubMed ID: 11431099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil.
    De Bruijn EA; Slee PH; Van Oosterom AT; Lameijer DW; Roozendaal KJ; Tjaden UR
    Pharm Weekbl Sci; 1988 Oct; 10(5):200-6. PubMed ID: 3205676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
    de Bruijn EA; Driessen O; Leeflang P; van Strijen E; van den Bosch N; Hermans J
    Cancer Treat Rep; 1987 Dec; 71(12):1267-9. PubMed ID: 3690535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of some anti-cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat.
    Skretkowicz J
    Pol J Pharmacol; 1995; 47(6):519-24. PubMed ID: 8868374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions of cyclophosphamide and 5-fluorouracil with methotrexate in an animal model.
    de Bruijn EA; Driessen O; Leeflang P; van den Bosch N; van Strijen E; Slee PH; Hermans J
    Cancer Treat Rep; 1986 Oct; 70(10):1159-65. PubMed ID: 3756938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
    Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
    Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.
    Benz C; DeGregorio M; Saks S; Sambol N; Holleran W; Ignoffo R; Lewis B; Cadman E
    Cancer Res; 1985 Jul; 45(7):3354-8. PubMed ID: 4005858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.